Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Impact of hepatic steatos… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection

Artikel i vetenskaplig tidskrift
Författare Johan Westin
Martin Lagging
Amar P Dhillon
Gunnar Norkrans
Ana Romero
Jean-Michel Pawlotsky
S. Zeuzem
Solko W Schalm
Elke Verheij-Hart
Francesco Negro
Gabriele Missale
Avidan U Neumann
Kristoffer Hellstrand
Publicerad i J Viral Hepat
Volym 14
Nummer/häfte 1
Sidor 29-35
ISSN 1352-0504 (Print)
Publiceringsår 2007
Publicerad vid Institutionen för biomedicin, avdelningen för infektionssjukdomar
Sidor 29-35
Språk en
Länkar dx.doi.org/1010.1111/j.1365-2893.20...
Ämnesord Adult, Antiviral Agents/ therapeutic use, Biopsy, Fatty Liver/ complications/virology, Female, Genotype, Hepacivirus/genetics/ growth & development, Hepatitis C, Chronic/ complications/ drug therapy/virology, Humans, Interferon Alfa-2a/ therapeutic use, Kaplan-Meiers Estimate, Kinetics, Male, Middle Aged, Polyethylene Glycols/ therapeutic use, RNA, Viral/blood, Ribavirin/ therapeutic use, Treatment Outcome
Ämneskategorier Medicin och Hälsovetenskap

Sammanfattning

Liver steatosis is highly prevalent in chronic hepatitis C virus (HCV) infection, especially in patients infected with genotype 3 virus, but its significance for the outcome of antiviral treatment is not fully understood. We have monitored steatosis in liver biopsies from 231 patients with chronic HCV infection who received pegylated recombinant interferon-alpha and ribavirin in a phase III study (DITTO trial). The degree of steatosis, along with relevant metabolic parameters, was correlated with the early disappearance of virus and with the final outcome of treatment. Our data suggest that the presence of steatosis impairs the early reduction of viral load during treatment in patients infected with HCV genotype 3 and non-3. Steatosis negatively affected the final outcome of treatment mainly in patients infected with HCV genotype non-3 virus. Based on these findings, we propose that interventions aiming at reducing hepatic steatosis prior to the onset of antiviral therapy may be of benefit to patients infected with HCV of the non-3 genotypes. Patients infected with genotype 3, on the other hand, should be offered early antiviral treatment.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?